Although no definitive studies have established how CD36 inhibitors may halt the progression of MASLD, and no CD36 inhibitors have been clinically approved for MASLD treatment, CD36 remains a promising target for further research. This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.